Status: Recruiting
Allo HSCT Using RIC and PTCy for Hematological Diseases
This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.
Participants needed: 56
Trial details
Phase: Phase 2Age: Up to 75Biological sex: AllType: InterventionalSponsor: Masonic Cancer Center, University of MinnesotaUpdated: Jul 1, 2025Locations: 1
Eligibility criteria
Age 0 to 75 years of age with Karnofsky score ≥ 70% (≥ 16 years) or Lansky score... [+12]
Pregnant or breast feeding. The agents used in this study include Pregnancy Cate... [+6]